BioXcel Therapeutics (BTAI) News Today $1.90 -0.03 (-1.55%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.87 -0.03 (-1.58%) As of 07/7/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial ... - MorningstarJuly 2, 2025 | morningstar.comMBioXcel Therapeutics Receives Positive DSMB Recommendation to Continue SERENITY At-Home Phase 3 Trial for BXCL501 - NasdaqJuly 2, 2025 | nasdaq.comBioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation...July 1, 2025 | markets.businessinsider.comBioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaJuly 1, 2025 | globenewswire.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 29, 2025 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Rating Lowered to "Sell" at Wall Street ZenJune 29, 2025 | americanbankingnews.comBTAI - BioXcel Therapeutics Inc Trailing Returns - MorningstarJune 27, 2025 | morningstar.comMBioXcel Therapeutics, Inc. (BTAI) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comBioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of ...May 29, 2025 | morningstar.comMBioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMay 27, 2025 | globenewswire.comBioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing RequirementMay 27, 2025 | globenewswire.comBank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)May 15, 2025 | theglobeandmail.comBioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comBank of America Securities Keeps Their Sell Rating on Bioxcel Therapeutics (BTAI)March 28, 2025 | markets.businessinsider.comBioXcel Therapeutics price target lowered to $1 from $4 at BofAMarch 28, 2025 | markets.businessinsider.comBioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024March 27, 2025 | globenewswire.comRodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy RecommendationMarch 20, 2025 | msn.comBioXcel Therapeutics initiated with a Buy at Rodman & RenshawMarch 19, 2025 | markets.businessinsider.comBioXcel Therapeutics strengthens cash position to advance SERENITY trialMarch 11, 2025 | markets.businessinsider.comBioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMarch 11, 2025 | globenewswire.comBioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trialMarch 7, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMarch 7, 2025 | globenewswire.comBofA maintains BioXcel Therapeutics stock underperform ratingMarch 5, 2025 | uk.investing.comBioXcel Therapeutics Announces Closing of $14 Million Registered Direct OfferingMarch 4, 2025 | globenewswire.comBioXcel Therapeutics announces $14M registered direct offeringMarch 4, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces $14 Million Registered Direct OfferingMarch 3, 2025 | globenewswire.comBioXcel Shares Are Up Today: What's Going On?March 3, 2025 | benzinga.comBioXcel announces FDA closed inspection of TRANQUILITY II Phase 3 trial siteMarch 3, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's DementiaMarch 3, 2025 | globenewswire.comBioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleFebruary 28, 2025 | globenewswire.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Down 84.3% in JanuaryFebruary 12, 2025 | marketbeat.comBTAI stock touches 52-week low at $2.53 amid sharp annual declineFebruary 11, 2025 | msn.comBioXcel Therapeutics trading halted, news pendingFebruary 8, 2025 | markets.businessinsider.comBioXcel Therapeutics enacts 1-for-16 reverse stock splitFebruary 7, 2025 | msn.comBioXcel Therapeutics announces 1-for-16 reverse stock splitFebruary 6, 2025 | msn.comBioXcel Therapeutics Sets 1-for-16 Reverse Stock Split To Regain Nasdaq ListingFebruary 6, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces Reverse Stock SplitFebruary 6, 2025 | globenewswire.comBioXcel Therapeutics provides clinical, business updateFebruary 5, 2025 | markets.businessinsider.comBioXcel Therapeutics Provides Clinical and Business UpdateFebruary 5, 2025 | finance.yahoo.comBioXcel Therapeutics advances key clinical trialsFebruary 5, 2025 | msn.comBioXcel Therapeutics stock target cut to $3 by H.C. WainwrightJanuary 30, 2025 | msn.comBioXcel Therapeutics stock hits 52-week low at $0.3January 30, 2025 | msn.comBioXcel Therapeutics price target lowered to $3 from $5 at H.C. WainwrightJanuary 30, 2025 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Bioxcel Therapeutics (BTAI)January 30, 2025 | markets.businessinsider.comBioXcel Therapeutics expands board, appoints new directorJanuary 16, 2025 | msn.comBioXcel Therapeutics files to sell 5.1M shares of common stock for holdersJanuary 10, 2025 | markets.businessinsider.comB of A Securities Downgrades BioXcel Therapeutics (BTAI)January 8, 2025 | msn.comBioXcel Therapeutics downgraded to Underperform from Buy at BofAJanuary 7, 2025 | markets.businessinsider.comBioxcel Therapeutics: Strategic Initiatives and Market Opportunities Drive Buy Rating Amid Financial ChallengesJanuary 7, 2025 | markets.businessinsider.comBioXcel Therapeutics price target lowered to $5 from $7 at CanaccordJanuary 7, 2025 | markets.businessinsider.com Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Media Mentions By Week BTAI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼1.140.57▲Average Medical News Sentiment BTAI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼41▲BTAI Articles Average Week Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Actinium Pharmaceuticals News Mural Oncology News Annovis Bio News Grace Therapeutics News Scilex News Medicus Pharma News Iterum Therapeutics News Pluri News Shattuck Labs News ABVC BioPharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts